 Connection
Samuel Ellis to Hypoglycemic Agents
This is a "connection" page, showing publications Samuel Ellis has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.505 |
|
|
|
-
Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother. 2015 Jan; 49(1):99-106.
Score: 0.283
-
Trujillo JM, Wettergreen SA, Nuffer WA, Ellis SL, McDermott MT. Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technol Ther. 2016 12; 18(12):749-758.
Score: 0.082
-
Libby AM, Pace W, Bryan C, Anderson HO, Ellis SL, Allen RR, Brandt E, Huebschmann AG, West D, Valuck RJ. Comparative effectiveness research in DARTNet primary care practices: point of care data collection on hypoglycemia and over-the-counter and herbal use among patients diagnosed with diabetes. Med Care. 2010 Jun; 48(6 Suppl):S39-44.
Score: 0.052
-
Garg SK, Bookout TR, McFann KK, Kelly WC, Beatson C, Ellis SL, Gutin RS, Gottlieb PA. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008 Oct; 10(5):369-75.
Score: 0.047
-
Ellis SL, Gemperline KA, Garg SK. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther. 2007 Jun; 9 Suppl 1:S48-56.
Score: 0.042
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|